Pulse Biosciences Inc ( (PLSE) ) has released its Q2 earnings. Here is a breakdown of the information Pulse Biosciences Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Pulse Biosciences Inc., a bioelectric medicine company, is pioneering the use of its proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology to improve patient outcomes in the healthcare sector. In its latest earnings report, Pulse Biosciences highlighted significant advancements in its clinical programs and financial results for the second quarter of 2025. The company expanded its pilot program for soft tissue ablation and made progress in its atrial fibrillation (AF) treatment studies, including FDA applications and positive clinical outcomes in Europe. Financially, Pulse Biosciences reported increased costs and expenses, primarily due to the expansion of its clinical trials and commercialization efforts, resulting in a GAAP net loss of $19.2 million for the quarter. Despite the losses, the company maintains a strong cash position with $106.3 million in cash and cash equivalents. Looking forward, Pulse Biosciences aims to continue advancing its clinical programs and leveraging its nsPFA technology to address unmet medical needs in various markets.